Effective management of chronic rhinosinusitis (CRS) continues to remain a challenge. Despite appropriate therapy, a significant proportion of CRS patients develop recurrent disease with substantial impact on their quality of life. However, recent years have witnessed major advances in laboratory research that have greatly expanded our understanding of the pathophysiology of CRS. Such insights have led to development of novel therapeutic options for recalcitrant disease. The purpose of this panel presentation is to discuss new, cutting-edge basic science research in rhinology and delineate how these findings have translated into innovative treatments for both chronic rhinitis and sinusitis. Current work aimed at defining CRS endotypes will be reviewed and their relationship to emerging systemic biologics addressed. The varied mechanisms of action, immunomodulatory capabilities, and clinical efficacy of these burgeoning agents will be elucidated in the context of CRS endotypes. The role of epithelial innate immunity and its clinical implications in CRS will also be assessed. Novel surgical approaches for recalcitrant CRS that have arisen from irrigation distribution studies will be delineated. The indications and techniques involved with such revision surgical salvage procedures will be described in conjunction with video presentations. Finally, new technologies will be presented along with the current evidence for their use in chronic rhinitis and sinusitis, including radiofrequency and cryoablation therapy. This session will be conducted by academic rhinologists using an interactive case-based format with audience polling.